Tecentriq

Active substance

Atezolizumab

Titulaire

Roche

Status

Closed

Indication

In combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small-cell lung cancer (ES-SCLC).

Public documents

Approbation

Information for the patient

Informed consent

Last update

01/10/2019